News >

Larotrectinib Achieves Over 90% Response in Pediatric Solid Tumors

Jason M. Broderick @jasoncology
Published: Tuesday, Dec 05, 2017

Brian Turpin, DO

Brian Turpin, DO
The novel pan-TRK inhibitor larotrectinib (LOXO-101) achieved a 93% response rate in pediatric patients with TRK fusion–positive solid tumors, according to findings from the phase I SCOUT trial presented at the AACR Special Conference on Pediatric Cancer.

The phase II portion of the SCOUT trial is now enrolling globally.
Turpin B, Albert CM, Mascarenhas L, et al. A pediatric phase 1 study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family: an updated analysis. Presented at: American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer Research; December 3-6, 2017; Atlanta, Georgia.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication